References

 

Back to Newsletter

http://www.alzheimerstreatments.com


(1). B. Vamosi et al (1976) “Comparative study of the effect of Vinpocetine and Xanthinol Nicotinate in cerebrovascular diseases” Arzneim Forsch (drug research) 28, 1980-84. Hereafter abbreviated “AF (DR)”)

(2). F. Solti et al (1976) “Effect of vinpocetine on the cerebral circulation” AF(DR) 28, 1945-47.

(3). E. Karpaty & L. Szporny (1976) “General and cerebral harmodynamic activity of Ethyl Apovincaminate” AF(DR)28, 1908-12.

(4). A. Szobor and M. Klein (1976) “Vinpocetine therapy in neurovascular disease” AF(DR) 28, 1984-89.

(5). D. Sauer et al (1988) “Vinpocetine prevents ischaemic cell damage in rat hippocampus” Life Sci. 43, 1733-39.

(6). R. Branconnier (1983) “The efficacy of the cerebral metabolic enhancers in the treatment of senile dementia.” Psychopharm Bull 19, 212-19.

(7). A. Hoffer & M. Walker, Smart Nutrients, Garden City Park, NY: Avery, 1994.

(8). C. Nicholson (1990) “Pharmacology of nootropics and metabolically active compounds in relation to their use in dementia.” Psychopharm 101, 147-59.

(9). K. Biro et al (1976) “Protective activity of vinpocetine on ischaemic anoxia of the brain” AF(DR)28, 1918-20.

(10). D. Hadjiev & S. Yancheva (1976) “Rheoencephalographic and psychological studies with vinpocetine in cerebral vascular insufficiency” AF(DR)28, 1947-50.

(11). A. Kaham & M. Olah (1976) “Use of vinpocetine in ophthalmological therapy” AF(DR)28, 1969-72.

(12). H. Olpe et al (1985) “Locus Coeruleus as a target for psychogeriatric agents” Ann NY Acad Sci 444, 399-405.

(13). B. Saletu & J. Grunberger (1985) “Memory dysfunction and vigilance; neurophysiological and psychopharmacological aspects” Ann NY Acad Sci 444, 406-27.

(14). O. Ribari et al (1976) “Vinpocetine in the treatment of sensorineuronal impairment of hearing” AF(DR)28, 1977-80.

(15). R. Balestreri et al (1987) “A double blind placebo controlled evaluation of the safety and efficacy of vinpocetine in the treatment of patients with chronic vascular senile cerebral dysfunction.” J. Am Geriatr Soc 35, 525-30.

(16). E. Otomo et al (1985) “Comparison of vinpocetine with Ifenprodil Tartrate and Dihyroergotoxine Mesylate treatment and results of long term treatment with vinpocetine.” Curr Ther Res 37, 811-21.

(17). E. Cholnoky & L. Domok (1976) “Summary of safety tests of Vinpocetine” AF(DR)28, 1938-44.
Kiss B, Karpati E, Mechanism of action of vinpocetine, Acta Pharm Hung 1996 Sep;66(5):213-24
Szakall S, et al. Cerebral effects of a single dose of intravenous vinpocetine in chronic stroke patients: a PET study. J Neuroimaging 1998 Oct;8(4):197-204
Feigin VL, et al. Vinpocetine treatment in acute ischaemic stroke a pilot single-blind randomized clinical trial.Eur J Neurol. 2001 Jan;8(1)81-5.

Bonoczk P, et al, Role of sodium channel inhibition in neuroprotection: effect of vinpocetine. Brain Res Bull2000 Oct;53(3):245-54.

 

Back to Newsletter